Cathie Wood's ARK shifts focus, buys Intellia stock, sells Roku and DraftKings

Cathie Wood's ARK ETFs executed notable portfolio shifts on August 28, 2025, divesting significantly from Roku (ROKU) with a $5.35 million sale of 55,624 shares via ARKK, following a series of sales. Conversely, ARK's largest purchase was 349,930 shares of Intellia Therapeutics (NTLA) for $3.99 million through ARKK, indicating growing confidence in the gene-editing firm. A further $2.61 million sale of 54,679 DraftKings (DKNG) shares across multiple ETFs underscores a broader strategic adjustment, as ARK reallocates capital from streaming and gaming towards biotechnology.

Analysis

On August 28, 2025, Cathie Wood's ARK ETFs executed a significant portfolio rebalancing, signaling a strategic pivot away from specific consumer technology and gaming names towards biotechnology. The firm's largest dollar-value trade was the divestment of 55,624 shares of Roku (ROKU) for approximately $5.35 million, which continues a consistent selling pattern observed over the past week. Similarly, ARK reduced its exposure to DraftKings (DKNG) by selling 54,679 shares for $2.61 million across three separate ETFs (ARKK, ARKW, ARKF), reinforcing a sustained divestment from the digital gaming company. In stark contrast, ARK's most significant purchase was a $3.99 million acquisition of 349,930 shares in Intellia Therapeutics (NTLA), a gene-editing firm. This purchase is part of a recent trend of accumulation, indicating strong institutional conviction in the biotech company's future. These trades collectively illustrate a clear capital rotation, channeling funds from the streaming media and sports betting sectors into what ARK perceives as a more promising area of disruptive innovation in healthcare.

Key Decisions for Investors

• Investors should interpret ARK's consistent, multi-day trading not as random noise, but as a deliberate strategic shift out of consumer media and gaming stocks and into high-conviction biotechnology plays.
• The persistent selling of Roku (ROKU) and DraftKings (DKNG) by a major growth-focused asset manager represents a significant bearish signal, warranting a review of positions for those holding these stocks.
• ARK's sustained accumulation of Intellia Therapeutics (NTLA) provides a strong bullish data point from a prominent institutional investor, suggesting that the risk/reward profile for the gene-editing firm may be favorable.